Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents of $237.37M in Q2 FY2026
Q2 FY2026 cash & equivalents was $237.37M.
Context
- Cash & equivalents amounted to 50.7% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 87.97M USD
- Year-over-year change
- —
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 87.97M | — |
Cash & Equivalents vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's Jun 2026 cash & equivalents of $237.37M is the 2nd highest of the 5 companies compared; the peer median is $114.99M.
- Cash & equivalents amounts to 50.7% of total assets for COAG, versus a peer median of 46.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
DMRADamora Therapeutics, Inc. | Mar 2026 | $532.9M | +4363.5% | +98.8% | 99.5% |
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | $237.37M | — | — | 50.7% |
| Mar 2026 | $139.99M | -35.6% | -29.4% | 18.0% | |
IRONDisc Medicine, Inc. | Sep 2026 | $89.98M | -36.0% | -22.3% | 12.9% |
| Mar 2026 | $41.3M | +179.4% | -18.0% | 75.8% | |
| Peer median (excluding COAG) | $114.99M | +71.9% | -20.2% | 46.9% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.